Regeneron Pharmaceuticals, Inc. · NASDAQ:REGN
Regeneron Pharmaceuticals — Shareholder Meeting (2026)
24 slides from Regeneron Pharmaceuticals's shareholder meeting presentation, 2026
Slide 1: Meeting Agenda
Meeting Agenda PROPOSALS 01 VOTING & VOTING 02 RESULTS • Election of Directors • Ratification of Independent • Registered Public Accounting Firm Advisory Vote on Executive COMPANY UPDATE 03 Compensation (“Say-on-Pay” Vote) QUESTIONS & ANSWERS 04 0
Slide 2: 2026 Annual Shareholder Meeting: Strategy & Business Update
2026 ANNUAL SHAREHOLDER MEETING Strategy & Business Update Leonard S. Schleifer, MD, PhD Co-Founder, Board Co-Chair, President & Chief Executive Officer 1
Slide 3: Note regarding forward-looking statements and non-GAAP financial measures
Note regarding forward-looking statements and non-GAAP financial measures This presentation includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company"), and actual even
Slide 4: 3
3
Slide 5: The landscape of biotechnology
The landscape of biotechnology Breakthrough science requires an ecosystem — and that ecosystem is under pressure. The policy environment Global competition Science is powerful — Time and capital is at an inflection point is intensifying but success is rare requirements are immense As Washington deba
Slide 6: What is most critical to protect American biomedical innovation leadership?
What is most critical to protect American biomedical innovation leadership? Treat domestic Fix the global cost Keep regulatory pathways Invest seriously in the manufacturing as imbalance sharp and smart talent pipeline strategic infrastructure • Other wealthy nations • Clear review processes • Ameri
Slide 7: The landscape of biotechnology
The landscape of biotechnology Breakthrough science requires an ecosystem — and that ecosystem is under pressure. The policy environment Global competition Science is powerful — Time and capital is at an inflection point is intensifying but success is rare requirements are immense As Washington deba
Slide 8: Leveraging the power of science to bring transformative medicines to patients... over and over
Integrate Genetics, Accelerate Deliver Proteomics and Innovation and Follow the Science Breakthrough Big Data R&D Productivity Medicines World’s largest DNA and Powerful toolkit of ~50 clinical programs across 15 internally-developed proteomics-linked healthcare proprietary, turnkey technology six c
Slide 9: Q1 2026 financial performance and pipeline developments
Q1 2026 financial Notable R&D Pipeline Advancements performance and pipeline developments • FDA approved for treatment of allergic fungal rhinosinusitis in patients aged 6y+ • Approved in Japan for treatment of moderate-to-severe bullous pemphigoid • Approved in U.S. and Europe for pediatric chronic
Slide 10: >1.4 million patients on therapy globally
Continued growth and expansion in multiple Type 2 indications Q1 2026 Dupixent global net sales of $4.9B (+31% YoY*) >1.4 million patients on therapy globally Dupixent global net product sales, in $ Millions Approved in NINE indications globally +31%* Chronic Spontaneous Urticaria (CSU) pediatrics a
Slide 11: Sustaining I&I leadership and unlocking new growth opportunities
Sustaining I&I leadership and unlocking new growth opportunities Leveraging learnings from Dupixent and disease biology to advance next-gen approaches to treat inflammatory diseases Pursuing multi-pronged approach to sustain Advancing broader allergy pipeline I&I leadership into the next decade into
Slide 12: EYLEA HD + EYLEA in the U.S.
EYLEA HD + EYLEA in the U.S. EYLEA HD + EYLEA remain the U.S. branded anti-VEGF category leader Goal to establish EYLEA HD as new U.S. Net Product Sales, standard of care for retinal diseases in $ Millions • Q1 2026 U.S. net product sales of $468M $393 $431 • Comprised ~50% of Q1 2026 aggregate EYLE
Slide 13: Strengthening EYLEA HD's best-in-class profile
Strengthening EYLEA HD’s best-in-class profile Recent label enhancements expected to broaden adoption to patients with RVO and to patients requiring more frequent dosing Macula Edema following Pre-Filled Syringe Maximized Dosing Flexibility Retinal Vein Occlusion (RVO) • Regulatory application resub
Slide 14: Key growth driver and foundational to oncology portfolio
Key growth driver and foundational to oncology portfolio Building on leadership in non-melanoma skin cancers with adjuvant CSCC launch; building share in advanced non small cell lung cancer Strong and consistent growth Libtayo global net product sales, • Q1 2026 global net sales of $438M (+48% YoY*)
Slide 15: Driving global Oncology growth through differentiated launches
Driving global Oncology growth through differentiated launches Positive early launch progress with Libtayo in adjuvant CSCC and Lynozyfic in r/r multiple myeloma Engaging with a broader range Libtayo is the only NCCN 10,000+ eligible patients Adjuvant CSCC of treating specialties Category 1 Preferre
Slide 16: Otarmeni FDA Approval Marks Breakthrough in Genetic Medicine
Otarmeni FDA Approval Marks Breakthrough in Genetic Medicine Otarmeni is the first and only in vivo gene therapy for OTOF-related hearing loss – and it’s free for eligible patients in the U.S. • First FDA-approved gene therapy to restore a neurosensory function to normal levels • Regeneron’s first a
Slide 17: Regeneron pipeline targets large opportunities across therapeutic categories
Regeneron pipeline targets large opportunities across therapeutic categories Immunology & Inflammation IL-13 Type 2 Indications IL-4 Type 2 Indications Ophthalmology IL-4xIL-13 bispecific§ Type 2 Indications Oncology & Heme-Onc REGN1908-1909 (FelD1) Cat Allergy Lynozyfic (BCMAxCD3) Multiple myeloma
Slide 18: Regeneron approved and investigational medicines across a diverse set of diseases
Regeneron approved and investigational medicines across a diverse set of diseases Phase 1 Phase 2 Phase 3 FDA-Approved † REGN5837 (CD22xCD28) ubamatamab (MUC16xCD3) odronextamab (CD20xCD3) ° REGN7945 (CD38xCD28) nezastomig (PSMAxCD28) linvoseltamab (BCMAxCD3) REGN17372 (GPRC5DxCD28) marlotamig (EGFR
Slide 19: Deploying capital to maximize long-term value creation
Deploying capital to maximize long-term value creation Disciplined capital allocation approach laying the foundation for Regeneron’s next wave of innovation Return Capital to Shareholders Leveraging external Rewarding shareholders Business Development Investing in world-class Internal Investment R&D
Slide 20: Do Well by Doing Good
Our responsible approach: “DO WELL BY SCIENCE Innovating to deliver DOING GOOD” groundbreaking medicines ACCESS Advancing access to medicine for patients PEOPLE Caring for those we work and live with – our colleagues and CULTURE communities OF ETHICS PLANET & INTEGRITY Protecting ecosystems essentia
Slide 21: Responding to the 2026 Ebola outbreak: Regeneron's science and preparedness in action
Responding to the 2026 Ebola outbreak: Regeneron’s science and preparedness in action Regeneron’s Inmazeb® was the first treatment approved by the U.S. FDA for Zaire Ebolavirus; has been used in 100s of patients Maftivimab, the most potent neutralizing antibody in Inmazeb, has shown broad activity i
Slide 22: 21
21
Slide 23: GAAP to Non-GAAP Reconciliations
GAAP to Non-GAAP Reconciliations for 2026 22
Slide 24: Abbreviations and Definitions
Abbreviations and Definitions Abbreviation Definition Abbreviation Definition Abbreviation Definition AAV Adeno-associated virus GLP-1 Glucagon-like peptide 1 R&D Research & Development ABR Auditory Brainstem Response RVO Retinal vein occlusion gMG Generalized myasthenia gravis siRNA Small interferi
Regeneron Pharmaceuticals — Shareholder Meeting (2026) on 6ix